A Study on the Efficacy and Safety of IPyC for HER2+ MBC

NCT06990347 · clinicaltrials.gov ↗

COMPLETED

Status

301

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Inetetamab and Pyrotinib Combined with Chemotherapy

Sponsor

Fujian Medical University